Federal Register / Vol. 62, No. 69 / Thursday, April 10, 1997 / Notices 17623

Respondents No. of respondents

No. of respondents/response

Avg.

burden/response

(in

hrs.)

Total burden (in

hrs.)

Daily Diary with Peak Flow (Trial Period) ............................................................................. 300 7 days ............. 0.25 525

Compliance Calls During the Trial Period ............................................................................. 300 2 phone calls .. 0.0833 50

Daily Dairy with Peak Flow (Weeks 1–6) ............................................................................. 220 42 days ........... 0.25 2310

Compliance Phone Calls (Week 1–6) ................................................................................... 220 12 phone calls 0.0833 220

Dated: April 4, 1997.

Wilma G. Johnson,

Acting Associate Director for Policy Planning

and Evaluation, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–9192 Filed 4–9–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

CDC Advisory Committee on HIV and

STD Prevention: Meeting

In accordance with section l0(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meeting.

Name: CDC Advisory Committee on HIV

and STD Prevention.

Times and Dates: 8:30 a.m.–4:30 p.m., May

1, 1997; 8:30 a.m.–4:30 p.m., May 2, 1997.

Place: Sheraton Colony Square Hotel,

Midtown Atlanta, 188 14th Street, NE.,

Atlanta, Georgia 30361

Status: Open to the public, limited only by

the space available. The meeting room will

accommodate approximately 100 people.

Purpose: This committee is charged with

advising the Director, CDC, regarding

objectives, strategies, and priorities for HIV

and STD prevention efforts including

maintaining surveillance of HIV infection,

AIDS, and STDs, the epidemiologic and

laboratory study of HIV/AIDS and STDs,

information/education and risk reduction

activities designed to prevent the spread of

HIV and STDs, and other preventive

measures that become available.

Matters to be Discussed: Agenda items will

include combined HIV and STD surveillance

systems; impact of managed care on HIV and

STD control efforts; prevention and treatment

of persons co-infected with TB and HIV; and

follow-up of CDC activities in response to the

Institute of Medicine report ‘‘The Hidden

Epidemic—Confronting Sexually

Transmitted Diseases.’’ Agenda items are

subject to change as priorities dictate.

Contact Person for More Information: Beth

Wolfe, Program Analyst, National Center for

HIV, STD, and TB Prevention, 1600 Clifton

Road, NE., Mailstop E–07, Atlanta, Georgia

30333, telephone (404) 639–8008.

Dated: March 31, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–9193 Filed 4–9–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Board of Scientific Counselors,

National Center for Infectious

Diseases: Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meeting.

Name: Board of Scientific Counselors,

National Center for Infectious Diseases

(NCID).

Times and Dates: 11 a.m.–5:30 p.m., May

1, 1997; 8:30 a.m.–2:30 p.m., May 2, 1997.

Place: CDC, Auditorium B, 1600 Clifton

Road, NE., Atlanta, Georgia 30333.

Status: Open to the public, limited only by

the space available.

Purpose: The Board of Scientific

Counselors, NCID, provides advice and

guidance to the Director, CDC, and Director,

NCID, in the following areas: Program goals

and objectives; strategies; program

organization and resources for infectious

disease prevention and control; and program

priorities.

Matters To Be Discussed: The agenda will

focus on:

1. NCID Update.

2. Scientific Updates:

a. Opportunistic Infections

b. CDC Genetics Initiative

c. Vaccines

d. Managed Care

3. Workgroup Sessions:

a. Vaccines Issues

b. Food Safety

c. Blood Safety

d. Antibiotic Resistance

e. CDC Emerging Infections Plan 1998–

2000

4. Workgroup Reports

5. Recommendations.

Other agenda items include

announcements/introductions; follow-up on

actions recommended by the Board in

December 1996; and consideration of future

directions, goals, and recommendations.

Agenda items are subject to change as

priorities dictate.

Written comments are welcome and should

be received by the contact person listed

below prior to the opening of the meeting.

Contact Person for More Information:

Diane S. Holley, Office of the Director, NCID,

CDC, Mailstop C–20, 1600 Clifton Road, NE.,

Atlanta, Georgia 30333, telephone 404/639–

0078.

Dated: March 31, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–9194 Filed 4–9–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Advisory Council for the Elimination of

Tuberculosis: Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following meeting.

Name: Advisory Council for the

Elimination of Tuberculosis (ACET).

Times and Dates: 8:30 a.m.–4:30 p.m.,

April 30, 1997; 8:30 a.m.–4:30 p.m., May 1,

1997.

Place: Sheraton Colony Square Hotel,

Midtown Atlanta, 188 14th Street N.E.,

Atlanta, Georgia 30361.

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 100 people.

Purpose: The Council advises and makes

recommendations to the Secretary of Health

and Human Services, the Assistant Secretary

for Health, and the Director, CDC, regarding

the elimination of tuberculosis. Specifically,

the Council makes recommendations

regarding policies, strategies, objectives, and

priorities; addresses the development and

application of new technologies; and reviews

the extent to which progress has been made

toward eliminating tuberculosis.

Matters to be Discussed: Agenda items

include TB in children; TB in the foreign

born; issues related to the laboratory